Markets

Market Nav

News Details

19/06/2025 10:00

Marksans Pharma’s UK arm Relonchem gets UK MHRA approval for Oxybutynin Oral Solution

Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its product Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution.